2[2]Kato H, Sugimura T,A kagi T,et al. Long term consequences of Kawasahi disease.A 10-to-2 1-year follow-up study of 594 patients[J].Circulation, 1996,94(60): 1379-1385.
4[4]Fakcini F, Trapanis,Turchini S,et al Immunological findings in kawasahi disease[J].clin Exp Rheumatol, 1997,15(6): 685 ～ 689
5[5]Yo shioa T,Matsutani T,Iwagami S,et al.polyclonal expansiow of TCRBV 2-and TCRBV6-bearing T cells in patients with kawasahi disease[J].Immunology, 1999,96(3):465～472
7[7]Jordan SC.Intravenous gamma-globulin therapy in systemic Iupus erythematosus and immune complex disease [J]. lin Immunol Immunopathol, 1989,53(S2): 164
二级参考文献17
1Nakamura Y, Yanagawa H, Ojima T, et al. Cardiac sequelae of Kawasaki disease among recurrent cases[J]. Arch Dis Child, 1998,78(2): 163 - 165.
2Jason J, Gregg L, Han A, et al. Immunoregulatory changes in Kawasaki disease[J]. Clin Immunol Immunopathol, 1997,84(3):296- 306.
3Mori M, Imagawa T, Yasui K, et al. Predictors of coronary artery lesions after intravenous gamma- globulin treatment in Kawasaki disease[J]. J Pediatr, 2000,137(2):177- 180.
4Falcini F, Trapani S, Turchini S, et al. Immunological findings in Kawasaki disease[J]. Clin Exp Rheumatol, 1997,15(6):685- 689.
5Yoshioa T, Matsutani T, Iwagami S, et al. Polyclonal expansion of TCRBV2-and TCRBV6- bearing T cells in patients with Kawasaki disease[J]. Immunology, 1999,96(3):465- 472
6Kuijpers TW, Wiegman A, Van Lier RA, et al. Kawasaki disease:a maturational defect in immune responsiveness[J]. J Infect Dis,1999,180(6):1869- 1877.
7Yamakawa R, Ishii M, Sugimura T, et al. Coronary endothelial dysfunction after Kawasaki dsease: evaluation by intracoronary injection of acetylcholine[J]. J Am Coll Cardiol, 1998,31(5):1074-1080.
8Dhillon R, Clarkson P, Donald AE, et al. Endothelial dysfunction late after Kawasaki disease[J]. Circulation, 1996,94(9):2103-2106.
9Takabasbi M.The endothelium in Kawasaki disease: the next frontier[J]. J Pediatr, 1998,133(2):177-179.
10Terai M, Yasukawa K, Narumoto S, et al. Vascular endothelial growth factor in acute Kawasaki disease[J]. Am J Cardiol, 1999,83(3):337 - 339.
5Lee TJ, Kim KH, Chun JK, et al. Low-dose methotrexate thera-py for intravenous immunoglobulin-resistant kawasaki disease[ J ]. Yonsei Med J, 2008,49:714 -718.
6Burns JC, Best BM, Mejias A, et al. Infliximab treatment of in-travenous immunoglobulin-resistant kawasaki disease [ J ]. J Pediatr, 2008, 153 : 833 - 888.
7Furukawa S, Matsubara T, Umezawa Y, et al. Serum levels of P60 Solu- ble tumor necrosis factor receptor during acute Kawaaski disease [ J ]. J Pediatr, 1994,24:721 - 725.
8Terai M, Shulman ST. Prevalence of coronary artery abnormalitiesin ka2 wasaki disease is highly dependent on gammaglobulin dose but inde pen2dent of salicylate dose[ J]. J Pediatr, 1997,131:888 - 893.
9Taubert KA. Epidemiology of Kawasaki dis-ease in theUnited States and worldwide[ J]. Prog Pediatr Cardio,1 1997, 6 : 181 - 185.
10Newburger IW, Taubert KA, Shulman ST,et a. 1 Summary and abstractof the seventh in-ternational kawasaki disease symposium: de-cember 4-7, 2001, Hakone, Japan[J]. Pediatr Res, 2003, 53: 153- 157.
